Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effectiveness, Superiority and Safety of EA on OAB:Multi-center Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether electroacupuncture is effective in the treatment of overactive bladder.


Options:
A: Inclusion Criteria:

* - Patients must be 18 years or older as well as willing and able to provide informed consent
* Patients with documented symptoms of overactive bladder including: urgency, frequency \>7 times per day, nocturia, urgency incontinence for at least 6 months
* Patients who have failed at least one anti-cholinergic medication defined as no change or unsatisfactory improvement in symptom severity after 6 weeks of a daily regimen

Exclusion Criteria:

* Patients younger than 18 years,
* Patients unable or unwilling to provide informed consent,
* Patients who are illiterate,
* Patients who are non-English speaking or reading,
* Patients with a current urinary tract infection
* Patients with a history of interstitial cystitis
* Patients who have a history of a bleeding disorder
* Patients who are currently on chronic anti-coagulation
* Patients who are have taken mirabegron in the past or are currently using it
* Patients currently undergoing acupuncture treatment for a different condition
* Patients who are currently undergoing pelvic floor physical therapy
* Patients who are currently undergoing or will undergo treatment for a urologic or gynecologic malignancy
* Patients who are currently pregnant
* Patients with an implanted pacemaker or AICD
* Patients with a history of uncontrolled or poorly controlled hypertension
B: Inclusion Criteria:

1. Clinical diagnosis of overactive bladder.
2. Frequent micturition.（average urinary frequency of ≥8 voids per day）
3. No relevant drug use within 2 weeks and no acupuncture treatment within 1 month before the study; not in other clinical trials.
4. Self-reported bladder symptoms ≥3 months
5. Capable of giving informed consent .
6. Capable and willing to follow all study-related procedures

Exclusion Criteria:

* Frequent micturition and urinary urgency are secondary to other diseases.
* Clinical diagnosis of simple stress urinary incontinence.
* Patients with urinary track infection and vagenal infection.
* Patients with implantable pelvic stimulator.
* Current use of electric therapy on pelvic area/back/legs.
* Current use of clostridium botulinum therapy on vesical or pelvic muscles.
* participation in any clinical inverstigation involving or impacting gynecological/urinary/renal function.
* Suffering from severe cardiac/hepatic/renal injury or cognitive disorder/aphasia/ dysphrenia/malnutrition, or in poor perform status and unable to cooperate.
* Patients in gestation and in lactation period.
* Patients in coagulation disorders or taking anticoagulation drugs.
* People with cardiac pacemaker or metal allergy.
* Patients having got eletroacupunture therapy or solifenacin in 4 weeks before the study.
* Patients are afraid of needles.
C: Inclusion Criteria:

* females meet the meet the diagnostic criteria of mixed urinary incontinence
* aged 35-75 years
* moderate and severe urinary incontinence with the urinary incontinence severity index between 3 and 9
* suffering from urinary incontinence at least for 3 months with the 72-h incontinence episode frequency≥2 in the baseline assessment
* voluntarily join the research and sign the informed consent

Exclusion Criteria:

* pure stress urinary incontinence, pure urgency urinary incontinence, overflow incontinence and neurogenic bladder
* medicine use for urinary incontinence or may affect the bladder function, or taking any non-drug therapy (such as electric stimulation, bladder training and pelvic floor muscle training) in the last month
* symptomatic urinary tract infection and non-functional urologic disease
* having ever undergone an operation for urinary incontinence or on the pelvic floor (including hysterectomy)
* pelvic organ prolapse degree ≥2
* residual urinary volume (RUV) \>30 mL
* maximum flow rate (Qmax) \<20 mL/s;
* be allergic to solifenacin or having contradictions for muscarine antagonist (such as urinary retention, gastric retention, myasthenia gravis, ulcerative colitis and angle closure glaucoma)
* diseases affect function of lower urinary tract, such as uncontrolled diabetes, multiple sclerosis, Alzheimer's disease, Parkinson's disease, spinal injury, cauda equina injury and multiple system atrophy.
* serious cardiovascular, pulmonary, cerebral, liver, kidney, hematopoietic system or psychiatric disease and cognitive impairment
* patients with severe renal dysfunction or moderate hepatic dysfunction who are using strong Cyp3a4 Inhibitor like ketoconazole
* unable or limited to walking, up and down stairs and running
* poor compliance with electroacupuncture, pelvic floor muscle training or drug
* pregnancy, lactation or within the 12 months after birth
* having a cardiac pacemaker, a metal allergy, or a severe needle phobia.
* volunteer of other trials
D: Inclusion Criteria:

* SUI history
* Positive stress test result
* Urodynamically confirmed SUI
* Postvoid residual urine volume \<50ml

Exclusion Criteria:

* Urge incontinence (overactive bladder or detrusor overactivity incontinence)
* Neurogenic bladder

Answer: B